Background:Platelet endothelial cell adhesion molecule(PECAM-1)is present in the vascular endothelium and plays important roles in various biological processes.Several recent studies have reported associations between...Background:Platelet endothelial cell adhesion molecule(PECAM-1)is present in the vascular endothelium and plays important roles in various biological processes.Several recent studies have reported associations between PECAM-1 and certain subtypes of cardiovascular diseases(CVDs).However,further research is necessary to clarify the causal effects of PECAM-1 on CVDs.To determine whether PECAM-1 and CVDs are causally associated,we conducted a two-sample Mendelian randomization(TSMR)study.Methods:Single nucleotide polymorphisms(SNPs)associated with PECAM-1 were used as instrumental variants(IVs)to estimate the causal effects of PECAM-1 on CVDs.Six SNPs were included in our TSMR study.The inverse-variance weighted(IVW)method was applied in the primary analysis.To confirm the initial results,we conducted several complementary analyses and pleiotropy analyses.Results:In the IVW analysis,higher genetically predicted PECAM-1 levels were associated with lower risk of coronary artery disease(CAD)(OR,0.835;CI,0.757–0.92;P=3×10-4)and myocardial infarction(MI)(OR,0.79;CI,0.709–0.881;P=2.03×10-5).Conclusions:The findings confirmed that elevated PECAM-1 levels may decrease the risk of CAD and MI.These results confirm the causal effect of PECAM-1 on CVDs and may facilitate further investigation of the mechanism of PECAM-1 in CVD pathogenesis.展开更多
[目的]研究血清PECAM-1表达与胃癌患者预后的相关性,了解其在胃癌发生发展过程中的作用。[方法]入组初诊的Ⅳ期胃癌患者56例,经组织病理确诊、符合本研究入组标准,于入院后未经治疗前采取外周血5ml,运用酶联免疫法（ELISA法）检测外周血...[目的]研究血清PECAM-1表达与胃癌患者预后的相关性,了解其在胃癌发生发展过程中的作用。[方法]入组初诊的Ⅳ期胃癌患者56例,经组织病理确诊、符合本研究入组标准,于入院后未经治疗前采取外周血5ml,运用酶联免疫法（ELISA法）检测外周血中PECAM-1蛋白的表达,分析胃癌患者外周血中PECAM-1蛋白表达水平与预后及临床病理特征的关系。[结果]56例患者的中位总生存时间（m OS）为446d。胃癌患者血清PECAM-1中位值为79.5ng/ml,以该值作为分界值将患者分为高浓度组和低浓度组,PECAM-1高浓度组的m OS低于PECAM-1低浓度组（360d vs 558d,P=0.012）。PECAM-1高浓度组与低浓度组间患者性别、年龄（≥60岁与〈60岁）、一线化疗方案（XELOX与SOX）及周期数（≤4周期与〉4周期）、是否接受二线以上化疗差异均无统计学意义,但PECAM-1低浓度组一线化疗疗效优于高浓度组（P=0.043）。[结论]Ⅳ期胃癌患者血清PECAM-1水平与一线化疗疗效及预后生存可能相关,PECAM-1水平高者预后差,一线化疗疗效差。展开更多
基金supported by grants from the Ministry of Science and Technology of China(2021YFA0804803 and 2022YFA1104204)National Natural Science Foundation of China(82421001,82230014,81930007,81470389,81500221,81930012,and 82241027)+5 种基金the National Science Fund for Distinguished Young Scholars(81625002)Shanghai Municipal Health Commission(2022JC013,2023ZZ02021,and GWVI-11.1-26)Shanghai Municipal Education Commission(SHSMU-ZDCX20210700)Shanghai Hospital Development Center(SHDC12022102)the Science and Technology Commission of Shanghai Municipality(22JC1402100 and 22DZ2292400)the Major Project of Natural Science Foundation of Hunan Province(Open Competition 2021JC0002).
文摘Background:Platelet endothelial cell adhesion molecule(PECAM-1)is present in the vascular endothelium and plays important roles in various biological processes.Several recent studies have reported associations between PECAM-1 and certain subtypes of cardiovascular diseases(CVDs).However,further research is necessary to clarify the causal effects of PECAM-1 on CVDs.To determine whether PECAM-1 and CVDs are causally associated,we conducted a two-sample Mendelian randomization(TSMR)study.Methods:Single nucleotide polymorphisms(SNPs)associated with PECAM-1 were used as instrumental variants(IVs)to estimate the causal effects of PECAM-1 on CVDs.Six SNPs were included in our TSMR study.The inverse-variance weighted(IVW)method was applied in the primary analysis.To confirm the initial results,we conducted several complementary analyses and pleiotropy analyses.Results:In the IVW analysis,higher genetically predicted PECAM-1 levels were associated with lower risk of coronary artery disease(CAD)(OR,0.835;CI,0.757–0.92;P=3×10-4)and myocardial infarction(MI)(OR,0.79;CI,0.709–0.881;P=2.03×10-5).Conclusions:The findings confirmed that elevated PECAM-1 levels may decrease the risk of CAD and MI.These results confirm the causal effect of PECAM-1 on CVDs and may facilitate further investigation of the mechanism of PECAM-1 in CVD pathogenesis.
文摘[目的]研究血清PECAM-1表达与胃癌患者预后的相关性,了解其在胃癌发生发展过程中的作用。[方法]入组初诊的Ⅳ期胃癌患者56例,经组织病理确诊、符合本研究入组标准,于入院后未经治疗前采取外周血5ml,运用酶联免疫法（ELISA法）检测外周血中PECAM-1蛋白的表达,分析胃癌患者外周血中PECAM-1蛋白表达水平与预后及临床病理特征的关系。[结果]56例患者的中位总生存时间（m OS）为446d。胃癌患者血清PECAM-1中位值为79.5ng/ml,以该值作为分界值将患者分为高浓度组和低浓度组,PECAM-1高浓度组的m OS低于PECAM-1低浓度组（360d vs 558d,P=0.012）。PECAM-1高浓度组与低浓度组间患者性别、年龄（≥60岁与〈60岁）、一线化疗方案（XELOX与SOX）及周期数（≤4周期与〉4周期）、是否接受二线以上化疗差异均无统计学意义,但PECAM-1低浓度组一线化疗疗效优于高浓度组（P=0.043）。[结论]Ⅳ期胃癌患者血清PECAM-1水平与一线化疗疗效及预后生存可能相关,PECAM-1水平高者预后差,一线化疗疗效差。
